Novo Nordisk

Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion

Retrieved on: 
Wednesday, January 3, 2024
Kidney, MRAS, AstraZeneca, Physician, Kidney disease, DMC, Nephrology, Weight loss, Prevalence, BMI, FLOW, Bayer, Diabetic nephropathy, Novo Nordisk, Chronic kidney disease, Proteinuria, Data monitoring committee, Patient, Obesity, MRA, DKD, ACE, SGLT2, Dialysis, CKD, Pharmaceutical industry

As the landscape grows more competitive, their role will be crucial in determining the success of brands like Farxiga and Jardiance.

Key Points: 
  • As the landscape grows more competitive, their role will be crucial in determining the success of brands like Farxiga and Jardiance.
  • This unique positioning compared to other agents was swiftly recognized by nephrologists, prompting them to express a clear preference for the brand.
  • Since the label expansion of Eli Lilly/Boehringer Ingelheim's Jardiance to include CKD, nephrologists have rapidly embraced this drug for both their DKD and non-diabetic CKD patients.
  • Several of these agents, including SGLT2 inhibitors and Kerendia, have demonstrated their effectiveness in slowing the progression of CKD.

Pacira Appoints Frank D. Lee as Chief Executive Officer

Retrieved on: 
Thursday, December 21, 2023
Marketing, Roche, Immunology, Infection, Business, Chemical engineering, Eli Lilly, Vanderbilt University, Janssen, Acquisition, Chairperson, MBA, Therapy, Cancer, Novo Nordisk, Novartis, Engineering, Genentech, Growth, Patient, Senior, Management

TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the “Board”) has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his roles as Chief Executive Officer and Chairman of the Board, effective January 1, 2024, and will remain with the company through August 2025 in an advisory capacity to help ensure a smooth transition. In connection with Mr. Stack’s retirement, the Board has elected Paul Hastings, Lead Independent Director, as Chair of the Board, also effective January 2, 2024.

Key Points: 
  • TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the “Board”) has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024.
  • Most recently he served as Chief Executive Officer and member of the board of directors of Forma Therapeutics from March 2019 through its acquisition by Novo Nordisk in October 2022.
  • Prior to joining Genentech, Mr. Lee spent approximately 13 years across Novartis, Janssen and Eli Lilly in engineering, manufacturing, sales/marketing and business development.
  • On December 20, 2023, in connection with Mr. Lee’s appointment as Chief Executive Officer, the Board approved the grant of inducement awards to Mr. Lee.

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

Retrieved on: 
Tuesday, December 12, 2023
Constellation, Entrepreneurship, Hospital, Genetic code, MIT, CMC, CRISPR, JD, PASTE, Brigham and Women's Hospital, DNA, MD, Doctor of Philosophy, Therapy, Investment, HR, Polaris Partners, Novo Nordisk, Novartis, Polaris, Patent, MorphoSys, Cas9, ARCH, ARCH Venture Partners, Gene expression, Bruker, Genetic heterogeneity, Gene, Merck, PGI, Genome, Enzyme, Fujifilm, Patient, GV, Intellia Therapeutics

Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others

Key Points: 
  • Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others
    WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Tome Biosciences , Inc., the programmable genomic integration company, has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI).
  • “PGI represents the maturation of editing technologies, breaking current barriers in genomic medicines discovery,” said Rahul Kakkar, MD, President and Chief Executive Officer.
  • “PGI is revolutionary in that we can finally reprogram the human genome with an elegance and efficiency previously unimaginable.
  • Tome has an exclusive license to the core PASTE technology, which includes granted US patent numbers 11,572,556, 11,827,881 and 11,834,658.

Bellevue Asset Management AG – Are healthcare stocks poised for a comeback?

Retrieved on: 
Thursday, December 21, 2023
Annual report, Post office box, Vertex Pharmaceuticals, Novo Nordisk, Investment, Capital, Intuitive Surgical, Diabetes, CRISPR Therapeutics, Montreux Healthcare Fund, SIX Swiss Exchange, ChatGPT, Acquisition, Artificial intelligence, Health care, Lux, Growth, AI, Grand Canal Dock, Eli Lilly, Economics, Judgement, Risk, University of Zurich, Clinical trial, AG, House, CNMV, Prospectus, Biotechnology, Hematology, Thermo Fisher Scientific, Doctor of Philosophy, DNA, Genome, Roche, History, Therapy, Failure, Health, D, Patient, Obesity, CHF, Medtech, South, TEL, Harmony Row, Research, SICAV, University, Federal Executive Boards, News, DSM-IV codes, Pharmaceutical industry, Medical device, Cryptocurrency, Libre, Amgen

Bellevue Asset Management AG – Are healthcare stocks poised for a comeback?

Key Points: 
  • Bellevue Asset Management AG – Are healthcare stocks poised for a comeback?
  • In his investment outlook for 2024, Cyrill Zimmermann, a member of Bellevue Asset Management’s Executive Board and Head of Healthcare Funds & Mandates, explains why it is probably only a matter of time before healthcare stocks are rediscovered by the wider investment community.
  • In view of this dynamic situation, Bellevue Asset Management launched Bellevue Obesity Solutions in November, a fund that invests in the most attractive companies across the entire value chain for obesity treatment and management.
  • Dr. Cyrill Zimmermann is Head of Healthcare Funds & Mandates and a member of the Executive Board of Bellevue Asset Management.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM

Retrieved on: 
Monday, November 13, 2023
Chronic kidney disease, LLP, Letter, FDA, Marketing, Hemofiltration, Health, Diabetes, News, Novo Nordisk, Pomerantz, CRRT

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Outset and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

For Private and Small-Cap Public Life Sciences Companies, Biotech Showcase™ to Set the Tone for the Industry in 2024

Retrieved on: 
Thursday, December 14, 2023
Health, Technology, Neurology, Other Health, Software, Pharmaceutical, Biotechnology, Therapy, Investment, Scientific American, Conference, Regeneron Pharmaceuticals, Drug discovery, Astellas Pharma, Khosla Ventures, Novo Nordisk

Demy-Colton and EBD Group ’s Biotech Showcase ™ opens in conjunction with JPM Week, January 8-10, 2024 in San Francisco.

Key Points: 
  • Demy-Colton and EBD Group ’s Biotech Showcase ™ opens in conjunction with JPM Week, January 8-10, 2024 in San Francisco.
  • Held at the Hilton San Francisco Union Square, Biotech Showcase™ focuses on how the biopharma industry can accelerate drug discovery and what’s hot in therapeutics development.
  • They join more than 1,300 investors, more than 70 members of the news media, and upwards of 340 public and private presenting companies across biotechnology and digital healthcare.
  • Conference registration provides attendees access to the full Biotech Showcase™ program, encompassing specialized events such as the DigiMed Showcase and Seed Showcase.

Nucleus RadioPharma Appoints Former McKesson, Novo Nordisk Executive Kathy Spencer-Pike as Chief Commercial Officer to Drive Business Growth

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Radiology, Health, Oncology, Erg, Organization, ERG, Sanofi, Nucleus, Multimedia, Patient, Radiopharmaceutical, Growth, Novo Nordisk, McKesson Corporation, Pharmaceutical industry, Pfizer

Nucleus RadioPharma , the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the appointment of Kathy Spencer-Pike as Chief Commercial Officer.

Key Points: 
  • Nucleus RadioPharma , the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the appointment of Kathy Spencer-Pike as Chief Commercial Officer.
  • As a seasoned veteran with decades of commercial experience at McKesson, Novo Nordisk, Sanofi and Pfizer, Ms. Spencer-Pike will be responsible for accelerating the growth of the startup following its oversubscribed $56M Series A in October.
  • Ms. Spencer-Pike follows a string of C-Suite appointments including Geoff Johnson, M.D., Ph.D. as Chief Scientific Officer, Kevin Haehl as Chief Development Officer and Mark Przekop as Chief Operating Officer.
  • Ms. Spencer-Pike previously was VP, Commercial Leader for Novo Nordisk, successfully leading the planning, development and execution of market and sales strategies, exceeding revenue goals.

New Research From K Health: AI Can Improve Hypertension Treatment in Primary Care Settings

Retrieved on: 
Thursday, November 30, 2023
Science, Cardiology, Software, Research, General Health, Health, Artificial Intelligence, Technology, ECG, Hypertension, Data science, Primary care, Risk, Artificial intelligence, JNC, Patient, Algorithm, Division, Machine learning, Stroke, MBA, Death, CDC, Conditional sentence, Mayo Clinic, Mayo Clinic Proceedings, AI, Physician, Digital health, Novo Nordisk, Blood pressure, Pharmaceutical industry, Nursing, Medical device, Medicine

Artificial Intelligence (AI)-driven Primary Care company K Health announces today the publication of its peer-reviewed research in Mayo Clinic Proceedings: Digital Health, which demonstrates how K Health’s AI can provide information that allows for more personalized hypertension treatment in patient-facing settings.

Key Points: 
  • Artificial Intelligence (AI)-driven Primary Care company K Health announces today the publication of its peer-reviewed research in Mayo Clinic Proceedings: Digital Health, which demonstrates how K Health’s AI can provide information that allows for more personalized hypertension treatment in patient-facing settings.
  • According to the CDC , hypertension affects nearly half of American adults and is a major risk factor for heart attack and stroke.
  • Optimal treatment has a proven role in reducing the risk of advanced disease and death, but historically, guidelines have been difficult to implement in day-to-day practice.
  • Key highlights from the publication:
    The model—which was built using anonymized patient data from 16,917 real-world primary care clinical cases—was designed and validated to help physicians personalize treatment and stabilize patients with hypertension at the point of care.

Aspect Biosystems Named to Fast Company’s 2023 List of the Next Big Things in Tech

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, Health Technology, Health, Medical Devices, Intelligence, Obesity, Disease, Therapy, Diabetes, Patient, Organization, Regenerative medicine, Aspect, BioSystems, Novo Nordisk, Partnership, Pharmaceutical industry

Aspect Biosystems is applying its full-stack tissue therapeutic platform to develop a novel class of cell-based tissue therapeutics that are biologically functional, immune protective, and suitable for surgical implantation.

Key Points: 
  • Aspect Biosystems is applying its full-stack tissue therapeutic platform to develop a novel class of cell-based tissue therapeutics that are biologically functional, immune protective, and suitable for surgical implantation.
  • Earlier this year, Aspect announced a precedent-setting partnership with Novo Nordisk worth over US$2.6 billion to develop bioprinted tissue therapeutics for diabetes and obesity.
  • “We’re honored to accept this recognition from Fast Company,” said Tamer Mohamed, CEO and co-founder of Aspect Biosystems.
  • We are thrilled to honor the organizations that are making them a reality.”
    Click here to see the final list.

GE HealthCare Showcases More Than 40 Innovations, Including AI-Enabled Imaging Technology Solutions Designed for Precision Care at RSNA23

Retrieved on: 
Sunday, November 26, 2023
Professional Services, Philanthropy, Mobile, Wireless, Health Technology, Other Science, Research, Fund Raising, Foundation, Science, Neurology, FDA, Radiology, Pharmaceutical, Oncology, University, Medical Devices, Education, Hospitals, Software, Networks, Internet, Hardware, Cardiology, Biotechnology, Data Management, Technology, Health, Human Resources, Wearables, Mobile Technology, Artificial Intelligence, RSNA, Annual general meeting, AIR, Patient, Algorithm, IHI, Diagnosis, Cancer, Stavanger University Hospital, Growth, Hospital, Triage, GE HealthCare, Vanderbilt University Medical Center, Food, IGS, Cardiovascular disease, ViewPoint, European, Molecular imaging, Deep learning, Development, AI, Imaging, Physician, DSM-IV codes, Novo Nordisk, Command center, Collection, HIV disease progression rates, Risk, Bill, History, Pulse, Partnership, Atrial fibrillation, ECG, Somatosensory system, Mass General Brigham, PTX, Intelligence, Workflow, Work, Mayo Clinic, AAMC, Medical imaging, Nursing, Medical device, Ventricular fibrillation

Each connected care solution is designed to better support clinicians, improve patient care, and increase health system efficiency at a time when healthcare system challenges include rising levels of radiologist burnout and shortages.

Key Points: 
  • Each connected care solution is designed to better support clinicians, improve patient care, and increase health system efficiency at a time when healthcare system challenges include rising levels of radiologist burnout and shortages.
  • By using GE HealthCare integrated technologies and diagnostics, clinicians deliver a more personal, precise, and human-focused approach across the care continuum.
  • GE HealthCare is exploring, along with clinical collaborators, how AI can help predict patient response to immunotherapies.
  • For more information on GE HealthCare and these innovative solutions at RSNA, visit Booth 7326, our press kit , or the RSNA 2023 events page .